Global Archives – Treatment Action Group

Response to Tuberculosis Treatment Trials Results Published and Presented During the 2022 Union World Conference on Lung Health

November 16, 2022
Dorrit Walsh

Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB) welcome the clinical trials results recently published and presented during the 2022 Union World Conference on Lung Health, which evaluated shorter regimens and treatment shortening strategies for drug-sensitive and drug-resistant tuberculosis.

Research Toward a Cure Trials

November 16, 2022
Dorrit Walsh

A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).

image that reads: Introduction: 1/4/6 x24 - a campaign to rally energy, political will & funding to end TB

1/4/6×24 Community Campaign Training Materials

November 11, 2022
Dorrit Walsh

Community engagement and mobilization will be key to winning equitable access to the short-course treatment and prevention regimens at the heart of the 1/4/6x24 Campaign. For everyone to benefit from the scientific progress that made these effective new preventive treatments…

Introducing 1/4/6×24: A Campaign That Draws Inspiration from the Past to Change the Trajectory of the Future Fight to End Tuberculosis

November 3, 2022
Dorrit Walsh

By Lindsay McKenna, Mike Frick, and Mark Harrington At the 24th International AIDS Conference in Montreal this summer, TAG, Partners In Health (PIH), and Médecins Sans Frontières (MSF) launched the 1/4/6x24 Campaign to accelerate equitable global uptake of newly discovered…

Community Representation in HIV Research: From Study Volunteers to Investigators

November 3, 2022
Dorrit Walsh

By Cheriko A. Boone, Abraham Johnson, and Richard Jefferys In a 1989 article by Dr. Anthony Fauci, “AIDS — Challenges to Basic and Clinical Biomedical Research” — which preceded Treatment Action Group’s founding by just a few years — he…

Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies

October 27, 2022
Dorrit Walsh

On November 16, 2022, please join TAG, INPUD and AfroCAB for our webinar “Community Mobilization to Ensure Health Systems’ Readiness for Long-Acting Therapies” at 8:00 a.m. EST / 02:00 p.m. CET / 05:30 IST.

Public Health Leaders, Researchers, and Activists Launch Global Campaign to Revolutionize Tuberculosis Prevention and Treatmnt with New, Shorter, Stronger, Safer, Evidence-Based Regimens

October 27, 2022
Dorrit Walsh

As public health leaders, researchers, and civil society activists acting in solidarity with communities affected by tuberculosis (TB), we are dismayed by the continued global backslide in progress against history’s oldest pandemic.

1 / 4 / 6 x 24

October 26, 2022
Dorrit Walsh

Inspired by the legacy of Dr. Paul Farmer, the 1 / 4 / 6 x 24 Campaign calls for the “staff, stuff, space, systems and support” necessary to make groundbreaking short-course TB prevention and treatment regimens accessible to all who need them as a human right by the end of 2024.

Storytelling to Support TB Preventive Treatment (TPT)

October 24, 2022
Dorrit Walsh

Storytelling is a tool that can help build understanding, support discussions between members of affected communities and other stakeholders, and aid in the identification of important issues and potential solutions. The storyboards on this page describe the experiences of people…

The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation

September 21, 2022
Dorrit Walsh

As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of ivermectin to fight malaria transmission, mdc-STM currently in preclinical stage, and developed by MedinCell.